# System Forecasting Report
**Generated:** 20251205_220623

## Executive Summary
The latest backtest run processed 1972 symbols, with an average MAPE of 3.89% and a median MAPE of 2.68%. No anomalies were detected, and guardrails were inactive, indicating no system issues. Importantly, there were no risk events, confirming that the system is functioning as expected without any portfolio rejections. The models trained during this run were all BaselineLinear, with no promotions achieved. Overall, the system is safe to proceed with further evaluations and optimizations.

## Performance Overview
*(Audience: quants)*
### Key Metrics
- **Total Symbols Processed:** 1972
- **Models Trained:** 1972
- **Average MAPE:** 3.89%
- **Median MAPE:** 2.68%

### Model Comparison
- All models trained were BaselineLinear, with 986 baseline wins and no challenger wins. This indicates that the BaselineLinear model remains the top performer across the evaluated symbols.

## Operational Insights
*(Audience: ops)*
### Guardrail Status
- **Guardrails:** Inactive
- **Total Checks:** 0
- **Passed:** 0
- **Warnings:** 0
- **Critical Issues:** None

### System Health
- The system is stable with no errors encountered during this run. No actions were executed, and the system is ready for the next operational phase.

## Research Insights
*(Audience: mixed)*
### Evaluation Insights
- Strong directional accuracy was observed across several symbols, including AAL_daily, AAL, AAPL_daily, AAPL, and AA_daily, all achieving 100% accuracy.

### Market Implications
- Current market implications are not available, but the high accuracy suggests robust model performance under the tested conditions.

## Key Opportunities
- Consider optimizing models further, especially exploring variations beyond BaselineLinear.
- Investigate potential enhancements in feature generation to improve model performance.

## Actions for Quants
- Evaluate the performance of BaselineLinear models and explore potential challengers for future runs.

## Actions for Ops
- Monitor system stability and prepare for the next operational phase, ensuring readiness for upcoming trials.

## Performance Overview (Legacy)
**Global Metrics:** N/A
**Symbol Performance:** N/A

## Risk Assessment (Legacy)
**Current Risks:**
